12:00 AM
 | 
Jan 03, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

TKM-PLK1: Phase I started

Tekmira began an open-label, dose-escalation, U.S. Phase I trial to evaluate TKM-PLK1 in up to 52 patients.

Tekmira Pharmaceuticals Corp....

Read the full 85 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >